Designing and Developing Green Drug Delivery Systems
Sagar Salave , Scientist, University of Kansas
Dr. Sagar Salave is a Scientist at the University of Kansas, USA, specializing in mRNA-LNP therapeutics and viral vaccine formulation. With a background in major pharmaceutical MNCs including Lupin and Ciron Drugs, he possesses extensive expertise in drug discovery and nanotechnology-driven R&D. He serves as an Associate Editor for Applied Biochemistry and Biotechnology Journal (Springer) and sits on the Editorial Board of several peer-reviewed journals. A prolific researcher with 70+ publications and ~1900 citations, he has further shaped the field through his work as a reviewer for ~45 international journals.
Abstract:
This expert talk explores sustainable paradigms in pharmaceutical formulation, focusing on "Green" drug delivery. By integrating biodegradable nanocarriers, solvent-free manufacturing, and Quality-by-Design (QbD) principles, we can minimise environmental impact. We evaluate how eco-friendly processing reduces hazardous waste while maintaining therapeutic efficacy and enhancing the thermal stability of next-generation therapeutics.
1. How are sustainability goals reshaping the design priorities of modern drug delivery systems across the pharmaceutical industry?
For a long time, the pharmaceutical industry designed drug delivery systems with just two main goals: patient safety and making sure the medicine worked. Today, environmental sustainability has become a critical third priority. Driven by stricter laws on plastic waste and a push to lower carbon footprints, companies are completely changing how they design these systems.
First, they are switching to better materials. Instead of using traditional petroleum-based plastics that stay in the environment forever, scientists are choosing biodegradable alternatives like natural plant fibers or special dissolving polymers. These new materials do their job inside the body and then break down safely without leaving harmful microplastics behind. Second, manufacturing is getting cleaner. Companies are replacing harsh, toxic chemical solvents with water-based options and switching to energy-efficient production methods that cut down on water and material waste.
Finally, medical devices themselves like inhalers and auto-injectors are getting a green makeover. Instead of throwing away a whole device after one use, new designs separate the complex parts so patients can reuse the electronic casing and only replace the medicine cartridge. By focusing on eco-friendly materials, cleaner factories, and reusable parts, the industry is proving that patient health and planet health can go hand in hand.
2. What are the most promising biodegradable nanocarrier platforms currently being explored for green drug delivery applications?
The most promising biodegradable nanocarrier platforms are divided into two main categories, both designed to deliver medicine effectively and break down completely without leaving toxic microplastics behind:
1. Natural Polymer Platforms: These are harvested from renewable biomass or upcycled organic waste, completely bypassing petroleum synthesis. Key examples include polysaccharides like chitosan (from seafood waste), sodium alginate (from seaweed), dextran, and hyaluronic acid, as well as protein carriers like gelatin, albumin, and zein (corn protein). These structures are naturally cleaved by human enzymes into harmless sugars or amino acids.
2. Synthetic Biodegradable Platforms: Though man-made, these are engineered to mimic natural degradation pathways. Key examples include PLGA (polylactic-co-glycolic acid), PLA (polylactic acid), PCL (polycaprolactone), PGA (polyglycolic acid), and poly (β-amino esters). Instead of relying on enzymes, they undergo simple chemical hydrolysis (breaking down via bodily moisture) into safe metabolic acids that the body easily excretes.
Ultimately, both natural and synthetic options ensure a zero-waste lifecycle, protecting both patient health and the environment.
3. How can pharmaceutical companies balance environmental responsibility with the need for high therapeutic efficacy and regulatory compliance?
Balancing environmental responsibility with high therapeutic efficacy and strict regulations is a major challenge, but pharmaceutical companies are succeeding by embedding green priorities directly into early drug design. Rather than treating sustainability as an afterthought, companies treat eco-friendly metrics as core quality features from day one.
To achieve high efficacy while cutting waste, manufacturers are shifting from massive, energy-intensive batch production to automated continuous manufacturing. For instance, using advanced microfluidics to build nanocarriers ensures near-perfect particle consistency for patients while drastically minimizing raw chemical waste.
Furthermore, companies maintain regulatory compliance by using data-driven tools like Process Mass Intensity to track and reduce material waste. They replace harsh, toxic organic solvents with safe, pre-validated alternatives like water or supercritical carbon dioxide. These green choices meet strict safety guidelines set by agencies like the FDA and EMA without compromising the purity, stability, or strength of the medicine.
4. In what ways is solvent-free manufacturing transforming pharmaceutical formulation and process development?
Solvent-free manufacturing is transforming drug development by completely eliminating harsh organic chemicals like chloroform or dichloromethane from the factory floor. Historically, these toxic liquids were necessary to dissolve and blend ingredients, but they required massive energy to dry and risked leaving dangerous chemical residues in the final medicine.
Today, companies use advanced mechanical and thermal technologies instead. Methods like hot-melt extrusion apply heat and pressure to melt and blend drugs at a molecular level, while supercritical carbon dioxide technologies act like a liquid during mixing and then vent away harmlessly as a dry gas. Because there is no liquid to evaporate, the slow, energy-intensive drying phase is entirely removed. This allows factories to switch to compact, fully automated continuous production lines. Ultimately, removing solvents creates a much safer product for patients, drastically slashes energy and water waste, and simplifies regulatory approvals.
5. What are the key technical and scalability challenges associated with implementing eco-friendly drug delivery technologies in commercial manufacturing?
While green drug delivery works well in small lab batches, scaling it up for commercial manufacturing creates major engineering bottlenecks. The first challenge is material consistency. Unlike predictable synthetic plastics, natural ingredients like chitosan or seaweed-derived alginate vary from batch to batch. This natural variation can unpredictably alter nanoparticle size and how quickly the medicine dissolves in a patient.
Second, building these tiny carriers requires precise fluid mixing inside microscopic channels. If a factory tries to speed up production by forcing larger volumes through these channels, the smooth flow becomes turbulent. This turbulence ruins particle uniformity, producing irregular, low-quality batches.
Finally, purifying these green formulas creates a bottleneck. Replacing toxic chemicals with water-based options means factories must spend massive amounts of energy drying the product. This intensive processing can easily destroy fragile bio-based carriers, making large-scale production incredibly difficult.
6. How does the integration of Quality-by-Design (QbD) principles support the development of sustainable and reproducible drug delivery systems?
Quality-by-Design (QbD) is a smart framework based on a simple idea: quality should be intentionally built into a medicine from day one, rather than tested for at the very end. When developing green drug delivery systems, QbD is essential because it bridges the gap between environmental sustainability and reliable, identical manufacturing results.
Eco-friendly ingredients, like natural plant or seaweed extracts, are notoriously variable from batch to batch. QbD solves this by forcing scientists to define "Critical Material Attributes" early on. By understanding exactly how raw variations affect the final product, engineers can tweak factory settings in real time to ensure every single dose remains perfectly uniform and effective. Furthermore, QbD creates a mathematical safe zone called a "Design Space." Within these pre-approved boundaries, manufacturing teams can actively optimize green goals like lowering energy use, shortening mixing times, or adjusting water-based formulas without needing to pause production for lengthy regulatory reviews.
Furthermore, QbD catches tiny errors before they ruin a batch. This drastically reduces discarded chemical waste, energy, and water, proving that building quality directly into the design space makes pharmaceutical manufacturing highly reproducible, cost-effective, and planet friendly.
7. What roles do advanced materials and green chemistry approaches play in improving the thermal stability of next-generation therapeutics?
Next-generation medicines, like fragile mRNA therapies, usually require expensive, ultracold freezers to stay effective. Today, advanced materials and green chemistry are solving this issue by helping these treatments survive at room temperature, eliminating the need for cold storage. One major breakthrough involves using natural, eco-friendly sugars like trehalose or sucrose during freeze-drying. These sugars create a protective, glass-like shield that locks fragile nanoparticles in place, preventing them from falling apart when exposed to heat. Together, these green techniques lock the medicine’s inner core safely in place, turning delicate formulas into durable, heat-resistant powders that can be shipped anywhere in the world without spoiling.
8. How are pharmaceutical manufacturers addressing the reduction of hazardous waste without compromising formulation performance or patient safety?
Pharmaceutical manufacturers are aggressively cutting hazardous chemical waste by using smarter, cleaner engineering. Historically, making medicine creates massive amounts of toxic chemical byproducts. Today, companies are replacing harsh heavy-metal catalysts with natural, engineered enzymes. These biological catalysts speed up reactions in mild, water-based environments, matching traditional chemical precision while eliminating accidental toxic side-products.
Additionally, factories are systematically phasing out hazardous organic solvents like chloroform and replacing them with safe alternatives like water or liquid carbon dioxide. These eco-friendly solvents are thoroughly pre-validated to ensure they do not alter the medicine's structure or strength.
9. Which emerging analytical and characterization technologies are critical for evaluating the stability and sustainability of green formulations?
To evaluate the stability of green formulations, scientists rely on advanced tools that check particle quality without destroying delicate, bio-based carriers. Nanoparticle Tracking Analysis uses lasers to watch individual particles move, instantly catching if natural ingredients like chitosan are clumping together.
For a closer look, Cryogenic Electron Microscopy flash-freezes samples, providing high-resolution 3D images of fragile carrier structures without using damaging chemicals. Finally, inline digital sensors continuously scan ingredients as they mix on the factory floor. By catching minor chemical shifts in real time, these tools prevent failed batches, drastically reducing waste while ensuring the medicine remains perfectly safe.
10. How do you foresee regulatory frameworks evolving to encourage the adoption of environmentally sustainable pharmaceutical manufacturing practices?
I foresee regulatory agencies shifting from strict gatekeepers to active partners by rewarding eco-friendly factories with faster drug approvals. Instead of burying companies in paperwork for making a green change, regulators will use flexible frameworks like Quality-by-Design, allowing manufacturers to swap out toxic chemicals for safe alternatives on the fly.
Additionally, I expect to see mandatory environmental scores added directly to drug applications, fast-tracking products with a lower carbon footprint. Ultimately, by giving green factories a massive competitive advantage, regulators will transform environmental sustainability from an expensive legal chore into a powerful business strategy.
11. What opportunities does green drug delivery create for biologics, personalized medicine, and temperature-sensitive therapeutics?
Green drug delivery creates major breakthroughs for next-generation medicines by solving their biggest stability and manufacturing challenges. For complex biologics, like antibodies, using eco-friendly natural hydrogels allows the medicine to be released slowly and safely inside the body. This shifts treatments from long, painful hospital IV drips to simple, sustained injections that patients can easily take at home.
In personalized medicine, traditional small-batch manufacturing creates too much toxic waste to be done locally. Green chemistry solves this by using safe, water-based ingredients and closed microfluidic systems, allowing hospitals to safely print custom genetic therapies on demand right at the patient’s bedside.
Finally, for temperature-sensitive therapeutics like mRNA, green approaches eliminate the expensive "ultracold chain." By mixing fragile genetic material with protective, bio-based sugars during freeze-drying, scientists create a glass-like shield. This locks the medicine in place, turning delicate liquids into stable, heat-resistant powders that can be safely shipped anywhere in the world without freezers.
12. How can cross-functional collaboration between formulation scientists, process engineers, and sustainability teams accelerate innovation in eco-friendly drug delivery?
Cross-functional teamwork accelerates green drug innovation by breaking down technical silos early in development. When formulation scientists, process engineers, and sustainability teams collaborate from day one, they replace slow, step-by-step guessing with smart design. Scientists provide safe, bio-based ingredients; engineers build scalable, energy-efficient machinery; and sustainability experts track water and chemical waste using real-time data. Together, they use Quality-by-Design to map out a flexible manufacturing space. This joint effort ensures that eco-friendly medicines are not just planet-friendly, but also perfectly uniform, highly stable, and quickly approved by regulators for patient use.
13. Looking ahead, what breakthrough innovations or industry shifts do you believe will define the future of green pharmaceutical formulation and drug delivery?
I foresee regulatory frameworks changing from rigid gatekeepers into active partners by rewarding eco-friendly factories with faster market entry. Instead of drowning companies in paperwork when they make an eco-friendly switch, regulators are using flexible "Quality-by-Design" rules. This allows manufacturers to seamlessly swap out hazardous chemical solvents for clean alternatives like water or liquid carbon dioxide within pre-approved, flexible boundaries without triggering lengthy delays.
Additionally, I expect global authorities to soon mandate standardized environmental scores directly on drug applications, fast-tracking products built with a low carbon footprint. By giving green factories a massive competitive advantage, regulators will transform environmental sustainability from an expensive legal chore into a brilliant business strategy.
